Johnson & Johnson vs. Eli Lilly: Which Healthcare Giant's Stock Is a Better Buy for 2027?

Key points

• Johnson & Johnson reported FY2025 revenue around $94.2 billion, up 6% from the prior year, with net income near $26.8 billion and a net margin about 28.5%, reflecting its diversified mix of drugs, devices, and partnerships such as the AbbVie collaboration for Imbruvica.
• Eli Lilly FY2025 revenue reached about $65.2 billion, a 44.7% rise year over year, with net income around $20.6 billion and a net margin near 31.7%, driven largely by high demand for GLP-1 therapies like Mounjaro and Zepbound.
• J&J carries regulatory and litigation risk, including a $5.5 billion talc-related settlement in 2026, and about 30% of revenue facing U.S. patent expiration by 2032, which could heighten generic competition.
• Lilly relies on a concentrated core: Mounjaro and Zepbound together account for about 56% of revenue, creating exposure to pricing, supply, and payer dynamics, even as the company expands its manufacturing footprint.
• J&J operates with a near 0.6x debt-to-equity ratio and roughly 1.0x current ratio, while Lilly sits around 1.6x and 1.6x, indicating Lilly’s higher leverage but solid short-term liquidity amid expansion.
• The two firms differ in growth profile: Lilly is viewed as the fastest-growing pharma stock with a premium valuation, while J&J is seen as an overlooked behemoth with a stronger defensive stance and a planned orthopedics separation that could alter its risk/return profile.
• Industry dynamics—patent cliffs for J&J, continued GLP-1 momentum for Lilly, and ongoing capital investments—will shape which stock offers better risk-adjusted upside for investors aiming into 2027.